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A nomogram to predict the 
probability of axillary lymph node 
metastasis in early breast cancer 
patients with positive axillary 
ultrasound
Si-Qi Qiu1,2,*, Huan-Cheng Zeng1,*, Fan Zhang3, Cong Chen4, Wen-He Huang1, 
Rick G. Pleijhuis5, Jun-Dong Wu1, Gooitzen M. van Dam6 & Guo-Jun Zhang1,3,7
Among patients with a preoperative positive axillary ultrasound, around 40% of them are pathologically 
proved to be free from axillary lymph node (ALN) metastasis. We aimed to develop and validate a model 
to predict the probability of ALN metastasis as a preoperative tool to support clinical decision-making. 
Clinicopathological features of 322 early breast cancer patients with positive axillary ultrasound 
findings were analyzed. Multivariate logistic regression analysis was performed to identify independent 
predictors of ALN metastasis. A model was created from the logistic regression analysis, comprising 
lymph node transverse diameter, cortex thickness, hilum status, clinical tumour size, histological 
grade and estrogen receptor, and it was subsequently validated in another 234 patients. Coefficient of 
determination (R2) and the area under the ROC curve (AUC) were calculated to be 0.9375 and 0.864, 
showing good calibration and discrimination of the model, respectively. The false-negative rates of the 
model were 0% and 5.3% for the predicted probability cut-off points of 7.1% and 13.8%, respectively. 
This means that omission of axillary surgery may be safe for patients with a predictive probability of 
less than 13.8%. After further validation in clinical practice, this model may support increasingly limited 
surgical approaches to the axilla in breast cancer.
Axillary lymph node (ALN) status is one of the most important prognostic factors in patients with primary 
breast cancer and provides critical information for making treatment decisions1,2. Axillary lymph node dissection 
(ALND) is a standard surgical approach for all patients in the 20th century to both assess ALN status and treat 
metastatic ALNs. However, as many as about 70% of early breast cancer patients exhibit no ALN metastasis. In 
these cases, ALND can be deemed as a significant overtreatment with its accompanying morbidity such as pain, 
shoulder range of motion impairment, arm lymphedema, and paresthesia or numbness3–6.
During the past 15 years, sentinel lymph node biopsy (SLNB) has been widely used as an alternative to ALND 
in clinically node negative patients. SLNB has improved the management of clinically ALN negative patients 
and reduced significantly morbidity. However, SLNB is an expensive and time-consuming procedure due to the 
need for pathological assessment of the SLN during the operation. Because of the significant risk of morbidity 
mentioned above and the disadvantages of SLNB, several randomized clinical trials were performed to assess 
if avoiding axillary surgery is safe in patients with low risk of ALN metastasis. The results from these studies 
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showed similar disease free survival and overall survival in patients with ALND or without any axillary surgery7,8. 
Nowadays, indications for the management of ALND become much stricter due to the promising results from 
several randomized controlled clinical trials, such as the AMAROS trial9–11. These trials demonstrated that either 
axillary radiotherapy9 or omission of further axillary surgery10,11 could be a safe alternative to ALND in highly 
selected patients with limited sentinel lymph node (SLN) metastasis, without compromising overall survival, nor 
regional disease control, although one study showed that an estimated 11–27% of patients have residual nodal 
disease which was not removed by surgery10.
Based on the above findings, there remains considerable doubt about the value of the SLNB in selected 
patients. A randomized trial has been launched in Italy to evaluate whether the SLNB can be safely omitted 
in patients with clinically negative ALN12. The result of the trial is still to be expected. Seventy-five percent of 
patients have pathologically negative axillary nodes in those with preoperative negative ultrasound13. Meanwhile, 
among patients with a preoperative positive ultrasound, around 40% have negative axillary nodes upon final 
pathological examination of ALND specimen14. Therefore, it is of great clinical relevance to select those patients 
that can safely omit axillary surgery or should not undergo either a SLNB or an ALND.
Clearly, there is a need for the development of a decision-making tool in order to reliably select patients 
unlikely having ALN involvement. The aim of this study is to develop and validate a model to predict the proba-
bility of ALN metastasis in early breast cancer patients with positive axillary ultrasound, providing a preoperative 
tool for assisting clinical decision-making. We generated the model with a training cohort of 322 patients and 
validated it in an additional set of 234 patients from the same institution. A nomogram was created as a graphical 
representation of the model. In addition, a user-friendly web-based calculator was developed to facilitate use of 
the model in a clinical setting while providing complete insight in the model’s parameters.
Results
Clinicopathological characteristics of patients. The descriptive clinicopathological characteristics of 
patients in the modeling and validation group are provided in Table 1. No statistically significant differences were 
found between the two groups, except for P53, estrogen receptor (ER), and ALN variables including number of 
lymph nodes detected by ultrasound, transverse diameter, cortical thickness and absence of hilum.
197 patients (61.2%) positively expressed P53 in the modeling group, compared with 191 patients (81.6%) in 
the validation group. With regard to ER, the positive expression rate between the modeling group and validation 
group were quite similar, being 63% and 66.7%, respectively. However, the distribution of ER positive patients 
in the two groups were quite different, with a larger percentage of patients being ER 2+ in the modeling cohort 
(17.7%) compared to the validation cohort (9.0%), and with relatively smaller percentage in ER 1+ (6.8% versus 
10.7%) and ER 3+ (38.5% versus 47.0%) in the modelling group. We considered that the difference might due to 
the relatively small number of patient population.
The absolute median number of transverse diameter and cortical thickness between the modeling group and 
the validation group matched closely, with 13 mm versus 15 mm, and both 4 mm, respectively. A total of 54.7% of 
patients lost their lymph node hilum in the validation group, compared with only 39.1% in the modeling group. 
More than one lymph node was found in 199 patients (61.8%) in the modeling group, compared with 166 patients 
(70.9%) in the validation group. Typical ultrasound findings of positive and negative lymph nodes are shown in 
Fig. 1.
Lymph node metastasis was detected in 163 patients (50.6%) in the modeling group, compared with 133 
patients (56.8%) in the validation group. Results of comparison of lymph node metastasis by clinicopathological 
variables in the modeling group are shown in Table 2.
Univariate and multivariate analyses in the modeling group. In the univariate analysis, factors that 
were significantly associated with ALN metastasis included clinicopathological variables of primary tumour 
including clinical tumour size (p = 0.037), histological grade (p < 0.001), ER (p = 0.002), progesterone recep-
tor (PR) (p = 0.001), molecular subtype (p = 0.009), and lymph node variables assessed by ultrasonography 
including number of nodes (p = 0.010), transverse diameter (p < 0.001) and longitudinal diameter of lymph 
node (p < 0.001), longitudinal-to-transverse ratio (p = 0.001), cortical thickness (p < 0.001), absence of medulla 
(p < 0.001), and absence of hilum (p < 0.001) (Table 3).
In the multivariate logistic regression analysis, transverse diameter (p = 0.044), cortical thickness (p = 0.002), 
absence of hilum (p = 0.001), clinical tumour size (p = 0.018), histological grade (p < 0.001), and ER (p = 0.001) 
were identified as independent predictors of ALN metastasis and were included in the predictive model. 
Histological grade III showcases the highest predictive value with an OR of 8.083, in comparison with grade I 
tumours (95% CI, 3.022-21.616) (Table 3).
Predictive equation, nomogram and web-based calculator. An equation, ln (p/1 − p) = 0.063 × a 
+ 0.277 × b + 1.420 × c + 1.502 × d1 + 2.090 × d2 + 0.305 × e + 0.379 × f − 5.710, was generated to evaluate the 
probability of ALN metastasis preoperatively based on the result from the multivariate logistic regression analysis 
in the modeling group.
The denotement of letters in the equation is as follows: p = the probability of ALN metastasis; a = transverse 
diameter of lymph node as detected by ultrasound in mm; b = cortical thickness of lymph node as detected by 
ultrasound in mm; c = hilum (0 if present, 1 if absent); d1 = histological grade 1 (0 if grade 1 (G1) or grade 3 (G3), 
1 if grade (G2)); d2 = histological grade 2 (0 if G1 or G2, 1 if G3); e = clinical tumour size in cm; f = ER (0 if− , 1 
if + , 2 if + + , 3 if + + + ).
A nomogram was developed based on the result of multivariate logistic regression analysis (Fig. 2). The 
nomogram comprises nine rows and representation of each row is as follows. The first row (Points) is the point 
assignment for each variable. For an individual patient, each variable is assigned a point value according to the 
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Characteristic Modeling No. (%) Validation No. (%) p-value
No. of Patients 322 (100%) 234 (100%) -
Age at diagnosis (year) 0.218
 < = 35 25 (7.8%) 12 (5.1%)
 > 35 297 (92.2%) 222(94.9%)
Menopausal status 0.155
 Premenopausal 182 (56.5%) 118 (50.4%)
 Postmenopausal 140 (43.5%) 116 (49.6%)
Clinical Tumor size (mm) 0.594
 Median (IQR) 30 (23, 40) 30 (24, 40)
Clinical tumor size 0.355
 T1 74 (23.0%) 44(18.8%)
 T2 223 (69.3%) 169(72.2%)
 T3 22 (6.8%) 21(9.0%)
 Unknown 3 (0.9%) 0(0.0%)
Tumor location 0.457
 UOQ 152 (47.2%) 118(50.4%)
 LQQ 42 (13.0%) 25(10.7%)
 UIQ 51 (15.8%) 43(18.4%)
 LIQ 15 (4.7%) 14(6.0%)
 Central 62 (19.3%) 34(14.5%)
Histological grade 0.085
 I 49 (15.2%) 24(10.2%)
 II 104 (32.3%) 95(40.6%)
 III 154 (47.8%) 113(48.3%)
 Unknown 15 (4.7%) 2(0.9%)
Histological type 0.49
 Ductal 294 (91.3%) 220(94.0%)
 Lobular 10 (3.1%) 5(2.1%)
 Other 18 (5.6%) 9(3.9%)
ER 0.006
 Negative 119 (37.0%) 78(33.3%)
 1+ 22 (6.8%) 25(10.7%)
 2+ 57 (17.7%) 21(9.0%)
 3+ 124 (38.5%) 110(47.0%)
PR 0.654
 Negative 132 (41.0%) 106(45.3%)
 1+ 38 (11.8%) 30(12.8%)
 2+ 63 (19.6%) 39(16.7%)
 3+ 89 (27.6%) 59(25.2%)
Her-2 0.336
 Negative 223 (69.3%) 153(65.4%)
 Positive 99 (30.7%) 81(34.6%)
Ki-67 0.08
 < = 14 51 (15.9%) 25(10.7%)
 > 14 268 (83.2%) 207(88.5%)
 Unknown 3 (0.9%) 2(0.8%)
P53 < 0.001
 Negative 117 (36.3%) 38(16.2%)
 Positive 197 (61.2%) 191(81.6%)
 Unknown 8 (2.5%) 5(2.2%)
VEGF-C 0.231
 Negative 75 (23.3%) 43(18.4%)
 Positive 222 (68.9%) 165(70.5%)
 Unknown 25 (7.8%) 26(11.1%)
Molecular subtype 0.622
 Luminal A 173 (53.7%) 119(50.9%)
 Luminal B 44 (13.7%) 38(16.2%)
Continued
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clinicopathological characteristics by drawing a vertical line between the exact variable value and the Points line. 
Subsequently, a total point score (row 8) can be calculated by summing all of the assigned points for the six var-
iables. The predictive probability of axillary metastasis can be obtained by drawing a vertical line between Total 
Points and Risk (the final row). In addition, a web-based calculator was developed to facilitate use of the model 
in a clinical setting. The web-based calculator is freely accessible at https://app.evidencio.com/models/show/170.
The mean predicted probability and mean actual rate of axillary metastasis in each decile were calcu-
lated. Calibration of the model was considered acceptable with R2 of 0.9375 (Fig. 3). The Hosmer-Lemeshow 
Goodness-of-Fit test resulted in a p value of 0.18, indicating that the model fits well. The model was then validated 
with an additional set of 234 patients from the same institution. The performance of the model was good with an 
AUC of 0.864 (Fig. 4).
Sensitivity, specificity, accuracy and false-negative rate (FNR) of the model for several predicted probability 
cut-off values in the validation group are shown in Table 4. The FNRs of the model were 0% and 5.3% for the 
predicted probability cut-off points of 7.1% and 13.8%, respectively.
Characteristic Modeling No. (%) Validation No. (%) p-value
 HER-2 enriched 51 (15.8%) 43(18.4%)
 Triple negative 54 (16.8%) 34(14.5%)
Lymph node detected by ultrasound 
Number 0.025
 1 123 (38.2%) 68(29.1%)
 > = 2 199 (61.8%) 166(70.9%)
Transverse diameter (mm) 0.005
 Median (IQR) 13 (10, 17) 15 (11, 18)
Longitudinal diameter (mm) 0.092
 Median (IQR) 7 (5, 9) 7 (5.75, 10)
Longitudinal to transverse ratio 0.441
 Median (IQR) 0.53 (0.44, 0.67) 0.53 (0.42, 0.67)
Cortical thickness (mm) 0.029
 Median (IQR) 4 (3, 6) 4 (3, 7)
Absence of medulla 0.522
 Yes 87 (27.0%) 69(29.5%)
 No 235 (73.0%) 165(70.5%)
Absence of hilum < 0.001
 Yes 126 (39.1%) 128(54.7%)
 No 196 (60.9%) 106(45.3%)
Lymph node metastases 0.147
 Yes 163 (50.6%) 133(56.8%)
 No 159 (49.4%) 101(43.2%)
Table 1. Comparison between modeling group and validation group by clinicopathological characteristics. 
UOQ: upper outer quadrant; UIQ: upper inner quadrant; LOQ: lower outer quadrant; LIQ: lower inner 
quadrant; IQR: Interquartile range, which is the 25th percentile, 75th percentile.
Figure 1. Ultrasound findings of positive and negative axillary lymph nodes. A positive lymph node (A) was 
detected in the left axilla with thickened cortex, and the hilum is disappeared. The diameters are 19 × 16 mm. 
A negative lymph node (B) was detected in the left axilla with normal cortex and hilum. The diameters of the 
lymph node are 21 × 6 mm.
www.nature.com/scientificreports/










(n = 322) p-value
Age at diagnosis (year) 0.785
 < = 35 12 (48.0%) 13 (52.0%) 25
 > 35 151 (50.8%) 146 (49.2%) 297
Menopausal status 0.632
 Premenopausal 90 (49.5%) 92 (50.5%) 182
 Postmenopausal 73 (52.1%) 67 (47.9%) 140
Clinical tumor size (mm) 0.007
 Median (IQR) 30 (25, 40) 30 (20, 40) 30 (23, 40)
Clinical tumor size < 0.001
 T1 23 (31.1%) 51 (68.9%) 74
 T2 131 (58.7%) 92 (41.3%) 223
 T3 7 (31.8%) 15 (68.2%) 22
 Unknown 2 (66.7%) 1 (33.3%) 3
Tumor location 0.626
 UOQ 72 (47.4%) 80 (52.6%) 152
 LOQ 21 (50.0%) 21 (50.0%) 42
 UIQ 25 (49.0%) 26 (51.0%) 51
 LIQ 9 (60.0%) 6 (40.0%) 15
 Center 36 (58.1%) 26 (41.9%) 62
Histological grade < 0.001
 I 10 (20.4%) 39 (79.6%) 49
 II 49 (47.1%) 55 (52.9%) 104
 III 101 (65.6%) 53 (34.4%) 154
 Unknown 3 (20.0%) 12 (80.0%) 15
Histological type 0.318
 Ductal 152 (51.7%) 142 (48.3%) 294
 Lobular 5 (50.0%) 5 (50.0%) 10
 Other 6 (33.3%) 12 (66.7%) 18
ER 0.013
 Negative 49 (41.2%) 70 (58.8%) 119
 1+ 8 (36.4%) 14 (63.6%) 22
 2+ 32 (56.1%) 25 (43.9%) 57
 3+ 74 (59.7%) 50 (40.3%) 124
PR 0.009
 Negative 54 (40.9%) 78 (59.1%) 132
 1+ 20 (52.6%) 18 (47.4%) 38
 2+ 32 (50.8%) 31 (49.2%) 63
 3+ 57 (64.0%) 32 (36.0%) 89
Her-2 0.788
 Negative 114 (51.1%) 109 (48.9%) 223
 Positive 49 (49.5%) 50 (50.5%) 99
Ki-67 0.821
 < = 14 25 (49.0%) 26 (51.0%) 51
 > 14 136 (50.7%) 132 (49.3%) 268
 Unknown 2 (66.7%) 1 (33.3%) 3
P53 0.954
 Negative 59 (50.4%) 58 (49.6%) 117
 Positive 100 (50.8%) 97 (49.2%) 197
 Unknown 4 (50.0%) 4 (50.0%) 8
VEGF-C 0.215
 Negative 34 (45.3%) 41 (54.7%) 75
 Positive 119 (53.6%) 103 (46.4%) 222
 Unknown 10 (40.0%) 15 (60.0%) 25
Molecular subtype 0.007
 Luminal A 98 (56.7%) 75 (43.3%) 173
Continued
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Discussion
A precise noninvasive evaluation of ALN status preoperatively, although challenging, is very important for optimi-
zation of the treatment plan for patients with early breast cancer. Efforts have been made to construct a more precise 
and reliable tool for assessing the ALN status by using one, (e.g. ultrasound or digital mammography (MMG)), or a 
combination (e.g. magnetic resonance imaging (MRI), ultrasound and MMG) of current imaging modalities used 
in breast cancer patients, but the accuracy kept varying with less satisfactory. The FNRs of axillary ultrasound exam-
ination for determining lymph node metastasis were reported as 16.7% and 22.9%15,16. When combined with other 
modalities, such as MRI, physical examination, MMG, or positron emission tomography/computed tomography 
(PET/CT), the FNRs declined slightly, but were still as high as 14–16.9%15,16. Besides, the MRI and PET/CT exami-
nations are too expensive to be routinely implemented in all patients. Diepstraten et al.13 reported that the FNRs of 
ultrasound-guided ALN biopsy ranged from 15% to 40%, with a pooled estimate of 25%, which was much higher 
than the overall FNR of SLNB reported by the American Society of Clinical Oncology (ASCO)17. Moreover, the 
ultrasound-guided lymph node biopsy is an invasive procedure, which may increase risks like blood vessel damage. 
Development of a noninvasive, more practical, reliable and accurate clinical decision-making tool for predicting the 
probability of ALN metastasis is of great importance in clinical practice.
In the present study, we developed a predictive model to estimate the probability of ALN metastasis in early 
breast cancer patients with positive axillary ultrasound findings. The model was well calibrated in the modeling 
group and showed good performance for evaluation of nodal metastasis in the validation group with an AUC of 
0.864. Some clinicopathological variables showed statistically significant differences between the modeling group 
and the validation group, which might be due to the relatively small sample size. Despite significant difference 
existed, the absolute median number of transverse diameter and cortical thickness between two groups matched 
closely. That explains why the model still performed well in the validation group, although transverse diameter 
and cortical thickness served as independent risk factors for node metastasis. Our result emphasizes the stability 
of the model when applied to a different set of patients. Since stability serves as one of the most important quality 
parameters for a well-developed model, the stability of our model showcased in this study provides us confidence 
that the model is generally applicable to other Asian patient populations, although further validation in inde-
pendent patient cohorts is desirable.
According to NSABP B-3218, micrometastastic disease was an independent prognostic factor for patients with ini-
tially negative SLN. Therefore, in our study, IHC staining was routinely performed to detect micrometastasis when no 
tumour cells were identified on H&E staining. In a multivariate analysis, six variables emerged as independent predic-
tors for ALN metastasis and were included in the final model. They were clinical tumour size, histological grade, ER, 
transverse diameter, cortical thickness and absence of hilum of the lymph node as detected by ultrasound. Tumour 
size and histological grade have been reported to be risk factors for ALN metastasis in many other studies19–24, as 
could be confirmed by our results. The predictive value of ER and PR status in previous studies was uncertain, with 










(n = 322) p-value
 Luminal B 26 (59.0%) 18 (41.0%) 44
 HER-2 enriched 17 (33.3%) 34 (66.7%) 51
 Triple negative 22 (40.7%) 32 (59.3%) 54
Lymph node detected by 
ultrasound Number 0.010
 1 51 (41.5%) 72 (58.5%) 123
 > = 2 112 (56.3%) 87 (43.7%) 199
Transverse diameter (mm) 0.001
 Median (IQR) 14 (10, 19) 12 (9, 15) 13 (10, 17)
Longitudinal diameter (mm) < 0.001
 Median (IQR) 8 (6, 10) 6 (5, 7) 7 (5, 9)
Longitudinal to transverse 
ratio 0.005
 Median (IQR) 0.57 (0.44, 0.71) 0.50 (0.43, 0.60) 0.53 (0.44, 0.67)
Cortical thickness (mm) < 0.001
 Median (IQR) 6 (4, 9) 3 (2, 4) 4 (3, 6)
Absence of medulla < 0.001
 Yes 73 (83.9%) 14 (16.1%) 87
 No 90 (38.3%) 145 (61.7%) 235
Absence of hilum < 0.001
 Yes 102 (81.0%) 24 (19.0%) 126
 No 61 (31.1%) 135 (68.9%) 196
Table 2. Comparison of axillary lymph nodes metastasis by clinicopathological variables. UOQ, upper 
outer quadrant; UIQ, upper inner quadrant; LOQ, lower outer quadrant; LIQ, lower inner quadrant; IQR, 
Interquartile range, which is the 25th percentile, 75th percentile.
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Characteristic
Univariate Multivariate
OR 95% CI P-value Coefficient OR 95% CI p-value
Age at diagnosis (year)
< = 35 1
> 35 1.120 0.495–2.536 0.785
Menopausal status
 Premenopausal 1
 Postmenopausal 0.898 0.578–1.395 0.632
Clinical tumor size (mm) 1.210 1.011–1.448 0.037 0.305 1.357 1.053–1.748 0.018
Clinical tumor size < 0.001
 T1 1
 T2 3.157 1.804–5.527 < 0.001
 T3 1.035 0.372–2.879 0.948
Tumor location 0.629
 UOQ 1
 LOQ 0.65 0.358–1.180 0.157
 UIQ 0.722 0.329–1.588 0.418
 LIQ 1.083 0.343–3.420 0.891
 Center 0.694 0.329–1.464 0.338
Histological grade < 0.001 < 0.001
 I 1 1
 II 3.475 1.570–7.689 0.002 1.502 4.492 1.644–12.271 0.003
 III 7.432 3.441–16.054 < 0.001 2.09 8.083 3.022–21.616 < 0.001
Histological type 0.300
 Ductal 1
 Lobular 0.935 0.265–3.296 0.916
 Other 0.425 0.144–1.253 0.121
ER 1.303 1.101–1.541 0.002 0.379 1.461 1.166–1.832 0.001
PR 1.338 1.121–1.597 0.001
Her-2 0.937 0.584–1.504 0.788
Ki-67
 < = 14 1
 > 14 1.072 0.589–1.950 0.821
P53 0.987 0.823–1.183 0.885
VEGF-C 1.266 0.981–1.633 0.070
Molecular subtype 0.009
 Luminal A 1
 Luminal B 1.105 0.565–2.165 0.77
 HER-2 enriched 0.383 0.199–0.737 0.004
 Triple negative 0.526 0.283–0.979 0.043
Lymph node detected by ultrasound 
Number
 1 1
 > = 2 1.817 1.153–2.865 0.010
Transverse diameter (mm) 1.08 1.034–1.127 < 0.001 0.063 1.065 1.002–1.132 0.044
Longitudinal diameter (mm) 1.351 1.213–1.505 < 0.001
Longitudinal-to-transverse ratio 9.798 2.494–38.491 0.001
Cortical thickness (mm) 1.653 1.451–1.883 < 0.001 0.277 1.319 1.106–1.571 0.002
Absence of medulla
 No 1
 Yes 8.401 4.477–15.765 < 0.001
Absence of hilum
 No 1
 Yes 9.406 5.494–16.104 < 0.001 1.42 4.137 1.799–9.514 0.001
Constant − 5 .710
Table 3. Univariate and multivariate analysis for factors associated with axillary lymph node metastasis. 
UOQ: upper outer quadrant; UIQ: upper inner quadrant; LOQ: lower outer quadrant; LIQ: lower inner 
quadrant; IQR: Interquartile range, which is the 25th percentile, 75th percentile; OR: Odds ratio; CI: Confidence 
interval.
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metastasis was found in tumours with negative expression of either ER25 or PR23,26. In this study, we found that ER 
overexpression was associated with higher probability of ALN metastasis. This finding may seem counterintuitive, but 
is similar to the findings from Bevilacqua et al.20. Although we do not know the actual reason of this phenomenon, we 
hypothesize that ER negative tumours may prefer hematogenous metastasis rather than lymphatic metastasis.
To the best of our knowledge, this is the first ALN metastasis predictive model mainly incorporating ultra-
sound parameters reported in the English literature. Preoperative axillary ultrasound is a simple test that is 
routinely used for assessing the clinical ALN status in breast cancer patients. According to previous reports, 
thickening of cortex and disappearance of hilum were associated with lymph node metastasis14,16. The result of 
our study is in line with those findings. In our final nomogram, transverse diameter, cortical thickness and hilum 
status were included as independent predictors of ALN metastasis. For an expert radiologist, axillary ultrasound 
can almost always identify lymph nodes and access the node morphology27–29. In that case, the three ultrasound 
parameters incorporated in our model could be easily obtained in almost all breast cancer patients, which will 
ensure the application of the model. Around 15–40% of patients with positive axillary ultrasound may have 
tumour-negative nodes on pathological evaluation14,30–32. Obviously, it is of great value to identify those patients 
preoperatively, for whom SLNB or even omitting surgical intervention may be a suitable option. We created the 
predictive model based on data from patients with positive axillary ultrasound findings in order to select those 
patients with a low risk of node metastasis.
Figure 2. Nomogram for predicting the probability of axillary lymph node metastasis. The nomogram 
comprises nine rows. The first row is the point assignment for each variable. For an individual patient, each 
variable is assigned a point value according to the clinicopathological characteristics by drawing a vertical line 
between the exact variable value and the Points line. Subsequently, a total point (row 8) can be obtained by 
summing all of the assigned points for the six variables. Finally, the predictive probability of axillary metastasis 
can be obtained by drawing a vertical line between Total Points and Risk (the final row).
Figure 3. Calibration of the predictive model in the modeling group. All patients were grouped into deciles 
according to their predicted probabilities. The mean predicted probability of each decile was plotted against the 
actual probability of axillary lymph node (ALN) metastasis. The reference line represents perfect equality of the 
predicted probability and the actual incidence of ALN metastasis. The coefficient of determination (R2) reflects 
the calibration of the model. The calibration of the model was considered acceptable with R2 of 0.9375.
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In our study, patients with a predictive probability of less than 7.1% presented with no apparent lymph node 
metastasis. When the predicted probability cut-off point was set at 13.8%, the FNR of the model was only 5.3%, 
much lower than the FNR of SLNB reported by ASCO (overall 8.4%, range 0–29%)17. In that condition, omis-
sion of SLNB appears to be acceptable after thorough discussion with patients, especially in elderly patients with 
comorbid conditions. The pathological ALN status is not the only determinant to decide whether a patient should 
receive systemic adjuvant therapy or not. Histological grade, molecular subtype, tumour type, tumour size, and 
age of the patient should also be taken into consideration. In our study, only two patients, with an estimated 
predictive value of less than 13.8%, did not receive systemic therapy according to local guidelines. That is to say, 
patients would not be undertreated in terms of systemic therapy although they did not receive axillary surgery. 
Our model could provide doctors with a tool to estimate the probability of ALN metastasis and help them weigh 
the risks and benefits of SLNB more appropriately. Ultimately, this may prevent selected patients from undergoing 
unnecessary axillary surgery and associated comorbidity.
To our knowledge, several models have been developed to predict the probability of ALN metastasis, with 
reported AUC ranging from 0.702 to 0.7920,21,33,34. Among these models, the model developed by Bevilacqua et 
al. from the Memorial Sloan-Kettering Cancer Center (MSKCC) in 2007 is the most widely used. The MSKCC 
model produced an AUC of 0.754 when validated in another patient cohort from the same center20. Subsequently, 
the model was validated in a German breast cancer patient cohort24 and two Chinese breast cancer patient 
cohorts25,33, with an AUC of 0.78, 0.71 and 0.73, respectively, all showing a reasonable ability in distinguishing 
patients with positive lymph nodes from those with negative nodes. The MSKCC model incorporates nine param-
eters (tumour type, pathological tumour size, lymphovascular invasion (LVI), tumour location, age, multifocality, 
nuclear grade, ER and PR), some of which are available only post-operatively, such as pathological tumour size, 
LVI, and multifocality. This may limit the clinical implication of the model, and thus a second surgical procedure 
might be needed. Two more predictive models reported by Takada et al.34 and Chen et al.33 also require param-
eters that are not available preoperatively. We believe that, when compared with those models, our model shows 
some advantages. First, our model contains only six variables that are all routinely available prior to surgery, e.g. 
histological grade and hormone receptor status can be obtained after core needle biopsy of the primary tumour. 
This is expected to facilitate the clinical utility of the model in different settings, irrespective of infrastructure. 
Second, our model showed an excellent discrimination, yielding an AUC of 0.864. By calculating the individual 
Figure 4. Receiver-operating characteristic (ROC) curve of the predictive model for the validation group. 
The reference line with a slope of 1 indicates an area under the ROC curve value of 0.5, which means that the 
probability of axillary lymph node (ALN) metastasis is equal to the toss of a coin. An area under the ROC curve 
(AUC) value of 1 represents perfect discrimination of a patient with positive ALN from the one with negative 

















< 7.1% 6 (2.6) 0 100 6 100 0
< 13.8% 19 (8.1) 1 99.2 17.8 94.7 5.3
< 18.2% 23 (9.8) 2 98.5 20.8 91.3 8.7
< 20% 29 (23.1) 5 96.2 23.8 82.8 17.2
< 30% 55 (23.5) 14 89.5 40.6 74.5 25.5
< 40% 78 (33.3) 16 88 61.4 79.5 20.5
Table 4. Sensitivity, specificity and accuracy of our model in low-risk predictive patients in validation 
group. Validation group (n = 234): patients with positive lymph node (n = 133, 56.8%); patients with negative 
lymph node (n = 101, 43.2%). ALN: axillary lymph node; FNR: false negative rate.
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probability of ALN metastasis using our user-friendly web-based calculator, doctors could inform their patients 
regarding their chances of having a positive ALN preoperatively. This knowledge will allow patients to better par-
ticipate in discussing the treatment strategy on axillary nodes and make an informed decision.
Although our model provides a promising predictive value in early breast cancer patients, it still has some 
limitations. First, the model was only validated in one small internal validation cohort (n = 234). It needs to 
be further validated in external validation groups to evaluate its predictive ability and generalizability. Second, 
risk factors like clinical tumour size, cortical thickness and transverse diameter of lymph node may differ when 
measured by different doctors due to inter-observer variability. Taking the above-mentioned into account, our 
model cannot be considered an alternative to SLNB, even in patients with a low predicted probability of ALN 
metastasis. Validation studies using independent datasets to judge our model on its merits are encouraged. After 
further validation in clinical practice, this model may support increasingly limited surgical approaches to the 
axilla in breast cancer.
Methods
Study design and patients population. This study enrolled a consecutive series of 322 patients with 
primary invasive early breast carcinoma treated at the Breast Center, Cancer Hospital of Shantou University 
Medical College from November 2009 to April 2014 for developing the predictive model. An additional set of 234 
consecutive patients treated at the same institution between May 2014 and November 2015 were enrolled as the 
validation group.
The inclusion criteria were female patients with early invasive breast cancer (clinical TNM stage according to 
the 7th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual35: T1-3 and N0-1), 
having positive axillary ultrasound findings (defined as at least one lymph node visible by ultrasound36), and 
receiving a successful SLNB or ALND. Patients with local advanced disease (TNM stage according to the 7th 
edition of the AJCC Cancer Staging Manual35: T4 or N2-3), neo-adjuvant treatment, or bilateral breast cancer 
were excluded.
All patients underwent a preoperative axillary ultrasound assessment using the IU22 (PHILIPS, The 
Netherlands) and ACUSON S2000 (SIEMENS, Germany) with a high-frequency transducer (12 to 15 MHz). 
Characteristics of lymph nodes including number of nodes, transverse diameter, longitudinal diameter, 
longitudinal-to-transverse axis ratio, cortical thickness, absence of medulla and absence of hilum were recorded. 
The ultrasound findings were reviewed and re-assessed by an experienced radiologist (C.C.) with more than 
10 years of experience in breast ultrasound imaging. Surgical treatment for the primary disease included 
breast-conserving surgery or mastectomy with or without breast reconstruction. Systemic and radiation therapy 
were performed according to the local clinical practice guideline.
We utilized each of the following variables: age at diagnosis, menopausal status, clinical tumour size, tumour 
location, histological type, histological grade, ER, PR, human epidermal growth factor receptor 2 (Her-2), Ki-67, 
P53, vascular endothelial growth factor C (VEGF-C), as well as molecular subtype, and all above-mentioned var-
iables of lymph node on ultrasonography. If more than one lymph node was detected, the variables were assessed 
on the lymph node most suspicious for metastasis.
Tumour tissues were obtained from paraffin embedded specimens for hematoxylin and eosin (H&E), immu-
nohistochemistry (IHC), and fluorescence in situ hybridization (FISH) staining. The technique of histopathologi-
cal analysis has been described previously37. Grading of invasive tumour was scored according to the Nottingham 
(Elston-Ellis) modification of the Scarf-Bloom-Richardson grading system. All nodes were examined postop-
eratively with serial section H&E staining. IHC staining was performed to determine whether micrometastasis 
(0.2–2 mm cancer foci) existed or not when no cancer cells were identified on H&E staining. ER37, PR37, P5337, 
and VEGF-C38 were considered positive if immunostaining was positive in more than 10% of tumour cells. Her-2 
positivity was defined as a score of 3+ on IHC37 or amplification on FISH39. Ki-67 was considered positive if 
nuclear staining of tumour cells was > 14% and negative if ≤ 14%19.
Statistical analysis. Differences of continuous variables between groups were analyzed using the 
Mann-Whitney U test. The chi-square test was performed to compare the rates between different groups. In the 
modeling group, a univariate analysis was performed to assess risk factors for ALN metastasis. Variables with 
a p-value less than 0.05 in the univariate analysis were included in a binary logistic regression analysis using a 
backward selection procedure in order to discover the independent risk factors of ALN metastasis. Variables with 
a p-value less than 0.05 in the multivariate analysis, as an independent risk factor, were included in an equation 
for predicting the probability of ALN metastasis. Coefficients for each variable and the constant in the equation 
were generated based on multivariate analysis. A nomogram was developed to be a graphic representation of the 
model. To calibrate the model, the patients in the modeling group were grouped into deciles with respect to their 
predicted probabilities of lymph node metastasis calculated by the equation. For each decile, the mean predicted 
metastatic probability was compared with the mean actual metastatic rate. The calibration was assessed graphi-
cally and by calculation of the coefficient of determination (R2). The predictive model was then validated with an 
additional set of 234 Chinese patients in the validation group. The receiver operating characteristic (ROC) curve 
was drawn, and the area under the curve (AUC) was used to assess the predictive accuracy of the model. Fit of 
the model was evaluated by the Hosmer-Lemeshow Goodness-of-Fit test. Two tailed p-values of less than 0.05 
were considered statistically significant. Statistical analysis was performed by using the statistical software SPSS 
(version 19, SPSS Inc., Chicago, IL) and “R” (version 3.1.0).
Ethical approval. This study has been approved by the Ethics Committee of the Cancer Hospital of Shantou 
University Medical College, and was performed in accordance with the ethical standards laid down in the 1964 
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declaration of Helsinki and all subsequent revisions. All persons mentioned in the paper gave their informed 
consent prior to inclusion in the study.
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